2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Great Hall AD
Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

717 The "≤1 bridge" strategy versus extended chemotherapy approach in pre-transplant therapy in high-risk AML

Xiaoyu Zhang, MD, Lulu Pan2, Mingyue Xu3, Donglin Yang4, Aimin Pang5, Yi He, MD6, Hui Wei, MD, PhD7, Guoyou Qin8, Erlie Jiang, MD9
1 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Department of Biostatistics, Key Laboratory of Public Health Safety of Ministry of Education, NHC Key Laboratory for Health Technology Assessment, School of Public Health, Shanghai, China
3 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 Department of Biostatistics, Key Laboratory of Public Health Safety of Ministry of Education, NHC Key Laboratory for Health Technology Assessment, School of Public Health, Shanghai, China
9 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for high-risk acute myeloid leukemia (HR-AML). Yet the optimal number of bridging chemotherapy cycles prior to transplantation remains elusive. A recent perspective argued that post-remission therapy before transplant should not be routinely given, but without sufficient supportive data. The ASAP trial reported that omission of salvage chemotherapy did not correlate with inferior outcome in patients with relapsed or refractory AML. A major challenge in real-world analyses is that the response to induction therapy determines consolidation versus salvage. Consequently, both the number of treatment cycles and the chemotherapy regimen are interdependent: patients who achieve CR receive consolidation therapy to deepen remission, whereas those with suboptimal responses undergo salvage therapy to overcome disease resistance. We hypothesized that a "≤1 Bridge" strategy, defined as induction plus no more than one additional chemotherapy cycle (≤2 total cycles), would achieve outcomes comparable to or better than more extended regimens (>2 total cycles) in patients who would proceed to allogeneic HSCT.

Methods: We retrospectively analyzed consecutive HR-AML patients (age ≥14) diagnosed according to the 2022 European LeukemiaNet (ELN) criteria who underwent allo-HSCT between 2019 and 2024. Patients were stratified by pre-transplant chemotherapy burden: the Limited group (induction plus ≤1 additional cycle, total ≤2 cycles) versus the Extended group (>2 cycles). Inverse probability of treatment weighting adjusted for confounders including age, HCT-CI, KPS, karyotype, MLL rearrangement, intensive induction, HSCT type, and ABO compatibility. Outcomes included overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). We performed stratified analyses by first-induction response (CR vs poor response) and exploratory analyses of pre-transplant MRD. The study complied with the Declaration of Helsinki and was approved by the institutional review board.

Results: A total of 435 HR-AML patients were included (median age: 41 years, range 15-70), of whom 282 achieved CR after the first induction and 153 had poor response. Among them, 199 received the Limited strategy (≤2 cycles) and 236 received the Extended strategy (>2 cycles). Median follow-up among survivors was 365 days post HSCT.

The Extended strategy correlated with significantly worse OS (HR=2.24, P=0.028) and DFS (HR=2.23, P=0.016) among patients who achieved CR after the first induction. The impact of pre-transplant MRD on DFS differed by pre-transplant chemotherapy strategy. In the Limited group, 1-year DFS was independent of MRD status (MRD−: 91.1% vs MRD+: 85.3%, P=0.254), whereas MRD positivity was associated with significantly worse 1-year DFS (MRD−: 83.8% vs MRD+: 68.3%, P=0.005) in the Extended group. Notably, the Limited MRD+ group achieved 1-year DFS similar to the Extended MRD− group (85.3% vs 83.8%).

Among patients with poor response to first induction, the Extended strategy did not improve OS (HR=1.01, P=0.971) or DFS (HR=1.06, P=0.878), despite yielding higher rates of pre-transplant MRD negativity (Extended: 57% vs Limited: 23%). Similar to the CR cohort, the impact of MRD on DFS was not observed in the Limited group (MRD−: 68% vs MRD+: 75%, P=0.469). In the Extended group, MRD negativity was associated with markedly improved 1-year DFS (MRD−: 92% vs MRD+: 47.9%, P<0.001). Additionally, exploratory molecular analyses suggested a potential benefit of the Limited strategy in patients harboring TP53 mutations, or U2AF1 mutations, although no significant interactions were detected.

Conclusion: Our findings suggest that the "≤1 Bridge" strategy was associated with superior outcomes in patients who achieved CR after the first induction. In these patients, timely transplantation improved outcomes independent of MRD status. For those with poor response to the first induction, additional cycles provided no survival benefit, unless MRD negativity was achieved. These results support a response-stratified framework that prioritizes early transplantation over MRD-based decisions in HR-AML.

Xiaoyu Zhang, MD: No relevant conflicts of interest to declare.